Patients with relapsed AML have a poor prognosis and limited responses to standard chemotherapy. Lenalidomide is an immunomodulatory drug that may modulate anti-tumor immunity. We performed a study to evaluate the safety and tolerability of lenalidomide with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory AML. Adult patients with relapsed/refractory AML were eligible for this phase I dose-escalation study. We enrolled 35 patients using a "3 1 3" design, with a 10 patient expansion cohort at the maximum tolerated dose (MTD). Lenalidomide was initially given days 1-14 and MEC days 4-8; due to delayed count recovery, the protocol was 
cladribine, cytarabine and filgrastim (CLAG). [6] [7] [8] [14] [15] [16] [17] Given this low rate of complete remission, previous studies have sought to augment the response rates by adding additional agents to the MEC backbone, such as lintuzumab, 9 cyclosporine, 13 or the multidrug-resistance inhibitor valspodar, 10 but these attempts have proven largely unsuccessful.
Lenalidomide is an immunomodulatory drug, FDA approved for the treatment of multiple myeloma and some types of myelodysplastic syndromes. 18, 19 It has also been found to have single-agent activity in relapsed and refractory AML. 20, 21 Doses of lenalidomide between 25
and 75 mg daily appear to have modest activity in relapsed AML and achieve complete remissions in a small subset of patients with refractory disease, with a maximum tolerated dose of 50 mg as monotherapy in AML. [20] [21] [22] [23] [24] In MDS with del(5q), lenalidomide has been shown to degrade casein kinase 1A1, resulting in death of malignant progenitor cells. 25, 26 The mechanism by which lenalidomide induces responses in AML is not fully known, but may relate to altered cell cycling, disruption of the marrow microenvironment, ubiquination of critical targets, or immune mediated cytotoxicity. 22, 27 Lenalidomide may alter the expression of various transcripts, including miR-181a, that have been associated with increased sensitivity to cytotoxic chemotherapy, 28, 29 possibly serving to prime leukemic cells prior to exposure to cytotoxic agents.
Given the established activity of lenalidomide in myeloid neoplasms, we performed a phase 1 study of lenalidomide immediately prior to standard MEC reinduction chemotherapy, to evaluate the safety and tolerability of this combination in patients with relapsed or refractory AML.
| M E TH ODS
This clinical trial was approved by the Institutional Review Board of the Dana Farber/Harvard Cancer Center and registered on clinicaltrials.gov (NCT01681537). All patients signed an informed consent, and the study was conducted in accordance with the Declaration of Helsinki.
The study included adult patients aged 18 to 70 with a diagnosis of AML according to the 2008 WHO criteria, and included patients who had either relapsed after or were refractory to one or more cycles of remission induction chemotherapy, according to standard International Working Group criteria. 30 Patients with secondary AML were eligible, as well as patients with biphenotypic leukemia. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and intact organ function including a left ventricular ejection fraction 50%, creatinine < 2 mg/dL with an estimated glomerular filtration rate 60 ml/min, a total bilirubin less than 1. 
| Genetic mutation analysis
Patient bone marrow samples underwent DNA sequencing of 95 recurrently mutated genes using an assay named the Rapid Heme Panel, to identify mutation and copy number status. To describe associations between mutation status and patient outcomes in this cohort, samples were taken at study entry and correlated with responses to therapy.
| Immune cell responses
Given that lenalidomide may modulate anti-tumor immunity in AML, 
| Statistical analysis
Patient and clinical characteristics at baseline were summarized as number and percentage for categorical variables, and median and ranges for continuous variables. All reported toxicities, regardless of attribution, were summarized by toxicity type and maximum grade, and sorted per the number of patients experiencing the toxicity. The maximum toxicity grade is based upon consolidated reports for each given toxicity for a given patient over time, by taking the maximum toxicity grade across the study period. CR was summarized as numbers and percentages with 90% confidence interval (CI), which was calculated using the exact binomial test. Because patients could be either primary refractory or relapsed at the time of enrollment, we calculated the predicted remission rate with standard intensive reinduction using a scale based upon the duration of first remission, primary refractory disease, and number of reinduction attempts. 33 
| R E SU LTS

| Patient characteristics
A total of 35 patients were enrolled and received the study treatment. Table S1 ).
| Toxicity profile
Toxicity data were collected for the 35 patients treated on study. A total of 3 dose limiting toxicities (DLT) were observed, all due to delayed count recovery beyond day 45. Two were observed during the escalation phase using 14-day lenalidomide dosing (n 5 2/6 pts in the 10 mg/ , thrombotic thrombocytopenic purpura (TTP) (n 5 1), hypokalemia (n 5 1), and hyperuricemia (n 5 1). All on-treatment deaths (grade 5 sepsis, n 5 1; infection, n 5 1; respiratory failure, n 5 2) were determined to be unrelated to the study drug. We evaluated early mortality with reinduction for this high risk population; the 30-day mortality rate was 6% while the 60 day mortality was 13%.
| Efficacy
Thirty-five out of 36 consented patients received the study treatment and were evaluable for efficacy. Twelve patients achieved a CR 
| Overall and disease free survival
Among those patients achieving CR, 6 patients subsequently relapsed and 1 died while in remission, for a median DFS of 6.4 months (range <1 to 32 months). The patient who died in remission had a transplant prior to relapse and enrollment on this study; she achieved CR with 100% donor chimerism, but developed severe gastrointestinal graft versus host disease and died from associated complications. Of the 8 patients who had prior transplant, 5 achieved CR, including the patient above; the other patients did not experience significant GVHD in remission. The median overall survival for the entire cohort was 11.5 months (Figure 1 ). The 1-year overall survival for the entire cohort was 44% (95%CI 24-62%) and the 2-year overall survival estimate was 39% (95%CI 20-57%). Examining only those patients treated at the MTD, the median overall survival was not reached, with a 1-year survival estimate of 61% (95%CI 26-83%).
| Stem cell transplantation
Transplantation was performed at the discretion of the treating physician after the patient had completed protocol therapy. Among all patients, a total of 16 went on to stem cell transplantation (46%), while one who had relapsed after a transplant prior to study enrollment subsequently received a donor lymphocyte infusion (3%). The 16 who went to transplant included 7 of the 12 patients who achieved CR/CRi, and 9 of the 23 patients who did not achieve remission with this regimen. The median survival was not yet reached among the 16 patients who underwent transplant, and they had a 1-year OS of 70% (95%CI 38-88%).
| Cytogenetic and mutational profile and response
Cytogenetic analysis done at study entry most commonly revealed normal cytogenetics (n 5 15, 43%). Ten patients had a monosomal karyotype or a complex karyotype with three or more abnormalities (29%).
Other recurrent abnormalities included chromosome 7 abnormalities (n 5 7) and chromosome 3 abnormalities (n 5 4). Of the patients with a normal karyotype, 5 achieved complete remission (33%). None of the patients with chromosome 3 abnormalities achieved CR, while 3 of 7 patients with chromosome 7 abnormalities achieved remission. Among the seventeen patients treated at the MTD (50 mg days 1-10); three of four patients harboring chromosome 7 abnormalities achieved CR.
One patient among these seventeen had del(5q31) and achieved a CRp. Another patient had monosomy 5 but did not respond. There did not appear to be a specific cytogenetic result that significantly correlated with response. 
| D ISC USSION
Management options for patients with refractory or relapsed leukemia are limited, with the most common approach consisting of cytotoxic chemotherapy to achieve remission followed by allogeneic stem cell transplantation. Historically, remission rates with MEC reinduction chemotherapy have been reported at approximately 18-26% (Supporting Information   Table S2 ). [9] [10] [11] [12] [13] In this phase I study, we found that lenalidomide given for Lenalidomide has been safely combined with other chemotherapy drugs with limited additional toxicity. [35] [36] [37] [38] The addition of lenalidomide to MEC chemotherapy did not appear to significantly increase the toxicities associated with this regimen when given over a 10 day period; only 2 patients died within the first month of therapy (30-day mortality 6%; 60-day mortality 13%). Initially, the treatment regimen dosed lenalidomide over a 14 day period; this was tolerated at the 5 mg daily dose, but at 10 mg daily there were 2 dose limiting toxicities related to prolonged cytopenias. Lenalidomide has been previously associated with cytopenias when given as monotherapy in other AML studies, 20, 22 and the prolonged cytopenias seen in the current study may have been ; there were DLTs of delayed count recovery at a lenalidomide dose of 25 mg daily, which was notably lower than the MTD in our current study. Similarly, studies combining lenalidomide either at a dose of 10-25 mg on days 1-21 during "7 1 3" induction, 23 or at a dose of 10-25 mg on days 6-21 after intermediate dose cytarabine, 24 were limited by toxicities. These findings, combined with the improved tolerability in the current study once amended to stop lenalidomide after day 10 of therapy, suggest that the duration of exposure or sequencing of drugs is critical when lenalidomide is combined with cytotoxic agents.
We performed mutational profiling as an exploratory analysis to determine potential markers of response to this treatment regimen. As expected for patients with relapsed and refractory disease, this cohort was enriched for patients with poor cytogenetic and molecular characteristics. Overall, there was not a clear pattern of response in this small and heterogeneous cohort of patients. Nonetheless, this regimen achieved remissions in many patients whose disease harbored alterations associated with historically poor responses, such as monosomy 7
and TP53 (1 of 2). Only one patient had del(5q31) in this cohort, along with a TP53 mutation, and this patient did achieve a CRi. In contrast, patients with NRAS mutations appeared to have lower response rates, with only 1 of 9 attaining a remission. Among the 17 patients treated at the MTD of lenalidomide 50 mg/d on days 1-10, 7 patients achieved CR or CRi (41%), although no clear dose-response relationship was observed in this relatively small study.
Among the treated patients on this study, nearly half subsequently received an allogeneic stem cell transplant, which is favorable when compared to other estimates of transplant rates in relapsed or refractory AML. 39 Nine of these patients did not achieve remission with study therapy, but later went onto stem cell transplantation.
Although this study was primarily focused on the rate of complete remission after MEC and lenalidomide, we did note an encouraging survival rate at one year, with a median survival of 11.5 months and 1 year OS of 44% in this high-risk patient cohort. It is possible that the addition of lenalidomide alters other processes related to disease response by modulating an immune response against the tumor cells.
We collected patient samples during treatment and exposed patient There are several limitations to this study, particularly related to drawing conclusions regarding efficacy given the Phase I nature of the study. Enrolled patients had heterogeneous clinical courses prior to study treatment and had a spectrum of underlying mutational profiles.
The one patient in this cohort with del(5q) did have a response; nonetheless, previous work showed only limited efficacy in del5q AML with lenalidomide monotherapy. 22 In this phase I study we found the combination of lenalidomide and MEC chemotherapy to be a well-tolerated with encouraging suggestion of efficacy, even among patients with highly resistant disease. This combination achieved a favorable remission rate and 1-year overall survival in comparison to historical controls. An encouraging proportion of patients were successfully bridged to an allogeneic stem cell transplant.
The mechanism of potential benefit from the addition of lenalidomide to cytotoxic chemotherapy is uncertain, but may relate in part to its immunomodulatory effects. We observed enhanced activation of CD41 and CD81 T cells following MEC and lenalidomide therapy. A phase II study to further explore the efficacy of and effects on the underlying immune response with this chemotherapy combination is planned.
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